バイオシミラーインスリングラルギンのグローバル市場 2021年：企業別、地域別、種類・用途別

• 英文タイトル：Global Biosimilar Insulin Glargine Market 2021 by Manufacturers, Regions, Type and Application, Forecast to 2026

• レポートコード：GIR-203B16070 • 出版社/出版日：GlobalInfoResearch / 2021年12月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、85ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医薬品

• 販売価格（消費税別）

Single User	￥522,000 (USD3,480)	▷ お問い合わせ
Multi User	￥783,000 (USD5,220)	▷ お問い合わせ
Corporate User	￥1,044,000 (USD6,960)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

バイオシミラーインスリングラルギン市場レポートは、世界の市場規模、地域および国レベルの市場規模、セグメント市場の成長性、市場シェア、競争環境、販売分析、国内および世界の市場プレーヤーの影響、バリューチェーンの最適化、最近の動向、機会分析、市場成長の戦略的な分析、製品発売、地域市場の拡大などに関する情報を提供します。 GlobalInfoResearchの最新の調査によると、世界のバイオシミラーインスリングラルギンの市場規模は2020年のxxx米ドルから2021年にはxxx米ドルと推定され、2020年から2021年の間にxxx％の変化があります。世界のバイオシミラーインスリングラルギンの市場規模は次の5年間でxxx％のCAGRで成長すると予想されます。 バイオシミラーインスリングラルギン市場は種類と用途によって区分されます。2016年～2026年において、量と金額の観点から種類別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。 種類別セグメントは次をカバーします。 ・プレフィルド、カートリッジ 用途別セグメントは次のように区分されます。 ・病院、小売薬局、その他 世界のバイオシミラーインスリングラルギン市場の主要な市場プレーヤーは以下のとおりです。 ・Eli Lilly、Gan&Lee、Tonghua Dongbao、United Laboratory、Geropharm、Biocon、Wockhardt 地域別セグメントは次の地域・国をカバーします。 ・北米（米国、カナダ、メキシコ） ・ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア） ・アジア太平洋（日本、中国、韓国、インド、東南アジア、オーストラリア） ・南アメリカ（ブラジル、アルゼンチン、コロンビア） ・中東およびアフリカ（サウジアラビア、UAE、エジプト、南アフリカ） 本調査レポートの内容は計14章あります。 ・第1章では、バイオシミラーインスリングラルギン製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。 ・第2章では、主要なバイオシミラーインスリングラルギンメーカーの企業概要、2019年～2021年までのバイオシミラーインスリングラルギンの価格、販売量、売上、市場シェアを掲載しています。 ・第3章では、主要なバイオシミラーインスリングラルギンメーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。 ・第4章では、2016年～2026年までの地域別バイオシミラーインスリングラルギンの販売量、売上、成長性を示しています。 ・第5、6章では、2016年～2026年までのバイオシミラーインスリングラルギンの種類別と用途別の市場規模、市場シェアと成長率を掲載しています。 ・第7、8、9、10、11章では、2016年～2021年までの世界の主要国での販売量、売上、市場シェア、並びに2021年～2026年までの主要地域でのバイオシミラーインスリングラルギン市場予測を収録しています。 ・第12、13、14章では、バイオシミラーインスリングラルギンの販売チャネル、販売業者、顧客、調査結果と結論、付録、データソースなどについて説明します。 ***** 目次(一部) ***** ・市場概要 ・メーカー情報（企業概要、製品概要、販売量、価格、売上）：Eli Lilly、Gan&Lee、Tonghua Dongbao、United Laboratory、Geropharm、Biocon、Wockhardt ・メーカー別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：プレフィルド、カートリッジ ・用途別分析2016年-2026年：病院、小売薬局、その他 ・バイオシミラーインスリングラルギンの北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・バイオシミラーインスリングラルギンのヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・バイオシミラーインスリングラルギンのアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・バイオシミラーインスリングラルギンの南米市場規模2016年-2026年：ブラジル、アルゼンチン ・バイオシミラーインスリングラルギンの中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論

The Biosimilar Insulin Glargine market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest research, the global Biosimilar Insulin Glargine size is estimated to be million in 2021 from USD million in 2020, with a change of % between 2020 and 2021. The global Biosimilar Insulin Glargine market size is expected to grow at a CAGR of % for the next five years.

Market segmentation
Biosimilar Insulin Glargine market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers
Pre-filled
Cartridge

Market segment by Application can be divided into
Hospital
Retail Pharmacy
Others

The key market players for global Biosimilar Insulin Glargine market are listed below:
Eli Lilly
Gan&Lee
Tonghua Dongbao
United Laboratory
Geropharm
Biocon
Wockhardt

Market segment by Region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 14 chapters:
Chapter 1, to describe Biosimilar Insulin Glargine product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Biosimilar Insulin Glargine, with price, sales, revenue and global market share of Biosimilar Insulin Glargine from 2019 to 2021.
Chapter 3, the Biosimilar Insulin Glargine competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Biosimilar Insulin Glargine breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2016 to 2026.
Chapter 5 and 6, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2016 to 2026.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2016 to 2021.and Biosimilar Insulin Glargine market forecast, by regions, type and application, with sales and revenue, from 2021 to 2026.
Chapter 12, 13 and 14, to describe Biosimilar Insulin Glargine sales channel, distributors, customers, research findings and conclusion, appendix and data source.

レポート目次

---

1 Market Overview
1.1 Biosimilar Insulin Glargine Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Biosimilar Insulin Glargine Revenue by Type: 2019 Versus 2021 Versus 2026
1.2.2 Pre-filled
1.2.3 Cartridge
1.3 Market Analysis by Application
1.3.1 Overview: Global Biosimilar Insulin Glargine Revenue by Application: 2019 Versus 2021 Versus 2026
1.3.2 Hospital
1.3.3 Retail Pharmacy
1.3.4 Others
1.4 Global Biosimilar Insulin Glargine Market Size & Forecast
1.4.1 Global Biosimilar Insulin Glargine Sales in Value (2016-2026))
1.4.2 Global Biosimilar Insulin Glargine Sales in Volume (2016-2026)
1.4.3 Global Biosimilar Insulin Glargine Price by Type (2016-2026) & (US$/Unit)
1.5 Global Biosimilar Insulin Glargine Production Capacity Analysis
1.5.1 Global Biosimilar Insulin Glargine Total Production Capacity (2016-2026)
1.5.2 Global Biosimilar Insulin Glargine Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Biosimilar Insulin Glargine Market Drivers
1.6.2 Biosimilar Insulin Glargine Market Restraints
1.6.3 Biosimilar Insulin Glargine Trends Analysis
2 Manufacturers Profiles
2.1 Eli Lilly
2.1.1 Eli Lilly Details
2.1.2 Eli Lilly Major Business
2.1.3 Eli Lilly Biosimilar Insulin Glargine Product and Services
2.1.4 Eli Lilly Biosimilar Insulin Glargine Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.2 Gan&Lee
2.2.1 Gan&Lee Details
2.2.2 Gan&Lee Major Business
2.2.3 Gan&Lee Biosimilar Insulin Glargine Product and Services
2.2.4 Gan&Lee Biosimilar Insulin Glargine Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.3 Tonghua Dongbao
2.3.1 Tonghua Dongbao Details
2.3.2 Tonghua Dongbao Major Business
2.3.3 Tonghua Dongbao Biosimilar Insulin Glargine Product and Services
2.3.4 Tonghua Dongbao Biosimilar Insulin Glargine Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.4 United Laboratory
2.4.1 United Laboratory Details
2.4.2 United Laboratory Major Business
2.4.3 United Laboratory Biosimilar Insulin Glargine Product and Services
2.4.4 United Laboratory Biosimilar Insulin Glargine Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.5 Geropharm
2.5.1 Geropharm Details
2.5.2 Geropharm Major Business
2.5.3 Geropharm Biosimilar Insulin Glargine Product and Services
2.5.4 Geropharm Biosimilar Insulin Glargine Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.6 Biocon
2.6.1 Biocon Details
2.6.2 Biocon Major Business
2.6.3 Biocon Biosimilar Insulin Glargine Product and Services
2.6.4 Biocon Biosimilar Insulin Glargine Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.7 Wockhardt
2.7.1 Wockhardt Details
2.7.2 Wockhardt Major Business
2.7.3 Wockhardt Biosimilar Insulin Glargine Product and Services
2.7.4 Wockhardt Biosimilar Insulin Glargine Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
3 Biosimilar Insulin Glargine Sales by Manufacturer
3.1 Global Biosimilar Insulin Glargine Sales in Volume by Manufacturer (2019-2021e)
3.2 Global Biosimilar Insulin Glargine Revenue by Manufacturer (2019-2021e)
3.3 Key Manufacturer Market Position in Biosimilar Insulin Glargine
3.4 Market Concentration Rate
3.4.1 Top 3 Biosimilar Insulin Glargine Manufacturer Market Share
3.4.2 Top 6 Biosimilar Insulin Glargine Manufacturer Market Share
3.5 Global Biosimilar Insulin Glargine Production Capacity by Company
3.6 Manufacturer by Geography: Head Office and Biosimilar Insulin Glargine Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Biosimilar Insulin Glargine Market Size by Region
4.1.1 Global Biosimilar Insulin Glargine Sales in Volume by Region (2016-2026)
4.1.2 Global Biosimilar Insulin Glargine Revenue by Region (2016-2026)
4.2 North America Biosimilar Insulin Glargine Revenue (2016-2026)
4.3 Europe Biosimilar Insulin Glargine Revenue (2016-2026)
4.4 Asia-Pacific Biosimilar Insulin Glargine Revenue (2016-2026)
4.5 South America Biosimilar Insulin Glargine Revenue (2016-2026)
4.6 Middle East and Africa Biosimilar Insulin Glargine Revenue (2016-2026)
5 Market Segment by Type
5.1 Global Biosimilar Insulin Glargine Sales in Volume by Type (2016-2026)
5.2 Global Biosimilar Insulin Glargine Revenue by Type (2016-2026)
5.3 Global Biosimilar Insulin Glargine Price by Type (2016-2026)
6 Market Segment by Application
6.1 Global Biosimilar Insulin Glargine Sales in Volume by Application (2016-2026)
6.2 Global Biosimilar Insulin Glargine Revenue by Application (2016-2026)
6.3 Global Biosimilar Insulin Glargine Price by Application (2016-2026)
7 North America by Country, by Type, and by Application
7.1 North America Biosimilar Insulin Glargine Sales by Type (2016-2026)
7.2 North America Biosimilar Insulin Glargine Sales by Application (2016-2026)
7.3 North America Biosimilar Insulin Glargine Market Size by Country
7.3.1 North America Biosimilar Insulin Glargine Sales in Volume by Country (2016-2026)
7.3.2 North America Biosimilar Insulin Glargine Revenue by Country (2016-2026)
7.3.3 United States Market Size and Forecast (2016-2026)
7.3.4 Canada Market Size and Forecast (2016-2026)
7.3.5 Mexico Market Size and Forecast (2016-2026)
8 Europe by Country, by Type, and by Application
8.1 Europe Biosimilar Insulin Glargine Sales by Type (2016-2026)
8.2 Europe Biosimilar Insulin Glargine Sales by Application (2016-2026)
8.3 Europe Biosimilar Insulin Glargine Market Size by Country
8.3.1 Europe Biosimilar Insulin Glargine Sales in Volume by Country (2016-2026)
8.3.2 Europe Biosimilar Insulin Glargine Revenue by Country (2016-2026)
8.3.3 Germany Market Size and Forecast (2016-2026)
8.3.4 France Market Size and Forecast (2016-2026)
8.3.5 United Kingdom Market Size and Forecast (2016-2026)
8.3.6 Russia Market Size and Forecast (2016-2026)
8.3.7 Italy Market Size and Forecast (2016-2026)
9 Asia-Pacific by Country, by Type, and by Application
9.1 Asia-Pacific Biosimilar Insulin Glargine Sales by Type (2016-2026)
9.2 Asia-Pacific Biosimilar Insulin Glargine Sales by Application (2016-2026)
9.3 Asia-Pacific Biosimilar Insulin Glargine Market Size by Region
9.3.1 Asia-Pacific Biosimilar Insulin Glargine Sales in Volume by Region (2016-2026)
9.3.2 Asia-Pacific Biosimilar Insulin Glargine Revenue by Region (2016-2026)
9.3.3 China Market Size and Forecast (2016-2026)
9.3.4 Japan Market Size and Forecast (2016-2026)
9.3.5 Korea Market Size and Forecast (2016-2026)
9.3.6 India Market Size and Forecast (2016-2026)
9.3.7 Southeast Asia Market Size and Forecast (2016-2026)
9.3.8 Australia Market Size and Forecast (2016-2026)
10 South America by Country, by Type, and by Application
10.1 South America Biosimilar Insulin Glargine Sales by Type (2016-2026)
10.2 South America Biosimilar Insulin Glargine Sales by Application (2016-2026)
10.3 South America Biosimilar Insulin Glargine Market Size by Country
10.3.1 South America Biosimilar Insulin Glargine Sales in Volume by Country (2016-2026)
10.3.2 South America Biosimilar Insulin Glargine Revenue by Country (2016-2026)
10.3.3 Brazil Market Size and Forecast (2016-2026)
10.3.4 Argentina Market Size and Forecast (2016-2026)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Biosimilar Insulin Glargine Sales by Type (2016-2026)
11.2 Middle East & Africa Biosimilar Insulin Glargine Sales by Application (2016-2026)
11.3 Middle East & Africa Biosimilar Insulin Glargine Market Size by Country
11.3.1 Middle East & Africa Biosimilar Insulin Glargine Sales in Volume by Country (2016-2026)
11.3.2 Middle East & Africa Biosimilar Insulin Glargine Revenue by Country (2016-2026)
11.3.3 Turkey Market Size and Forecast (2016-2026)
11.3.4 Egypt Market Size and Forecast (2016-2026)
11.3.5 Saudi Arabia Market Size and Forecast (2016-2026)
11.3.6 South Africa Market Size and Forecast (2016-2026)
12 Sales Channel, Distributors, Traders and Dealers
12.1 Sales Channel
12.1.1 Direct Marketing
12.1.2 Indirect Marketing
12.2 Biosimilar Insulin Glargine Typical Distributors
12.3 Biosimilar Insulin Glargine Typical Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer

List of Tables
Table 1. Global Biosimilar Insulin Glargine Revenue by Type, (USD Million), 2021-2026
Table 2. Global Biosimilar Insulin Glargine Revenue by Application, (USD Million), 2021-2026
Table 3. Eli Lilly Basic Information, Manufacturing Base and Competitors
Table 4. Eli Lilly Major Business
Table 5. Eli Lilly Biosimilar Insulin Glargine Product and Services
Table 6. Eli Lilly Biosimilar Insulin Glargine Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 7. Gan&Lee Basic Information, Manufacturing Base and Competitors
Table 8. Gan&Lee Major Business
Table 9. Gan&Lee Biosimilar Insulin Glargine Product and Services
Table 10. Gan&Lee Biosimilar Insulin Glargine Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 11. Tonghua Dongbao Basic Information, Manufacturing Base and Competitors
Table 12. Tonghua Dongbao Major Business
Table 13. Tonghua Dongbao Biosimilar Insulin Glargine Product and Services
Table 14. Tonghua Dongbao Biosimilar Insulin Glargine Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 15. United Laboratory Basic Information, Manufacturing Base and Competitors
Table 16. United Laboratory Major Business
Table 17. United Laboratory Biosimilar Insulin Glargine Product and Services
Table 18. United Laboratory Biosimilar Insulin Glargine Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 19. Geropharm Basic Information, Manufacturing Base and Competitors
Table 20. Geropharm Major Business
Table 21. Geropharm Biosimilar Insulin Glargine Product and Services
Table 22. Geropharm Biosimilar Insulin Glargine Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 23. Biocon Basic Information, Manufacturing Base and Competitors
Table 24. Biocon Major Business
Table 25. Biocon Biosimilar Insulin Glargine Product and Services
Table 26. Biocon Biosimilar Insulin Glargine Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 27. Wockhardt Basic Information, Manufacturing Base and Competitors
Table 28. Wockhardt Major Business
Table 29. Wockhardt Biosimilar Insulin Glargine Product and Services
Table 30. Wockhardt Biosimilar Insulin Glargine Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 31. Global Biosimilar Insulin Glargine Sales by Manufacturer (2019-2021e) & (K Units)
Table 32. Global Biosimilar Insulin Glargine Revenue by Manufacturer (2019-2021e) & (USD Million)
Table 33. Market Position of Manufacturers in Biosimilar Insulin Glargine, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2020
Table 34. Global Biosimilar Insulin Glargine Production Capacity by Company, (K Units): 2020 VS 2021
Table 35. Head Office and Biosimilar Insulin Glargine Production Site of Key Manufacturer
Table 36. Biosimilar Insulin Glargine New Entrant and Capacity Expansion Plans
Table 37. Biosimilar Insulin Glargine Mergers & Acquisitions in the Past Five Years
Table 38. Global Biosimilar Insulin Glargine Sales by Region (2016-2021e) & (K Units)
Table 39. Global Biosimilar Insulin Glargine Sales by Region (2021-2026) & (K Units)
Table 40. Global Biosimilar Insulin Glargine Revenue by Region (2016-2021e) & (USD Million)
Table 41. Global Biosimilar Insulin Glargine Revenue by Region (2021-2026) & (USD Million)
Table 42. Global Biosimilar Insulin Glargine Sales by Type (2016-2021e) & (K Units)
Table 43. Global Biosimilar Insulin Glargine Sales by Type (2021-2026) & (K Units)
Table 44. Global Biosimilar Insulin Glargine Revenue by Type (2016-2021e) & (USD Million)
Table 45. Global Biosimilar Insulin Glargine Revenue by Type (2021-2026) & (USD Million)
Table 46. Global Biosimilar Insulin Glargine Price by Type (2016-2021e) & (US$/Unit)
Table 47. Global Biosimilar Insulin Glargine Price by Type (2021-2026) & (US$/Unit)
Table 48. Global Biosimilar Insulin Glargine Sales by Application (2016-2021e) & (K Units)
Table 49. Global Biosimilar Insulin Glargine Sales by Application (2021-2026) & (K Units)
Table 50. Global Biosimilar Insulin Glargine Revenue by Application (2016-2021e) & (USD Million)
Table 51. Global Biosimilar Insulin Glargine Revenue by Application (2021-2026) & (USD Million)
Table 52. Global Biosimilar Insulin Glargine Price by Application (2016-2021e) & (US$/Unit)
Table 53. Global Biosimilar Insulin Glargine Price by Application (2021-2026) & (US$/Unit)
Table 54. North America Biosimilar Insulin Glargine Sales by Country (2016-2021e) & (K Units)
Table 55. North America Biosimilar Insulin Glargine Sales by Country (2021-2026) & (K Units)
Table 56. North America Biosimilar Insulin Glargine Revenue by Country (2016-2021e) & (USD Million)
Table 57. North America Biosimilar Insulin Glargine Revenue by Country (2021-2026) & (USD Million)
Table 58. North America Biosimilar Insulin Glargine Sales by Type (2016-2021e) & (K Units)
Table 59. North America Biosimilar Insulin Glargine Sales by Type (2021-2026) & (K Units)
Table 60. North America Biosimilar Insulin Glargine Sales by Application (2016-2021e) & (K Units)
Table 61. North America Biosimilar Insulin Glargine Sales by Application (2021-2026) & (K Units)
Table 62. Europe Biosimilar Insulin Glargine Sales by Country (2016-2021e) & (K Units)
Table 63. Europe Biosimilar Insulin Glargine Sales by Country (2021-2026) & (K Units)
Table 64. Europe Biosimilar Insulin Glargine Revenue by Country (2016-2021e) & (USD Million)
Table 65. Europe Biosimilar Insulin Glargine Revenue by Country (2021-2026) & (USD Million)
Table 66. Europe Biosimilar Insulin Glargine Sales by Type (2016-2021e) & (K Units)
Table 67. Europe Biosimilar Insulin Glargine Sales by Type (2021-2026) & (K Units)
Table 68. Europe Biosimilar Insulin Glargine Sales by Application (2016-2021e) & (K Units)
Table 69. Europe Biosimilar Insulin Glargine Sales by Application (2021-2026) & (K Units)
Table 70. Asia-Pacific Biosimilar Insulin Glargine Sales by Region (2016-2021e) & (K Units)
Table 71. Asia-Pacific Biosimilar Insulin Glargine Sales by Region (2021-2026) & (K Units)
Table 72. Asia-Pacific Biosimilar Insulin Glargine Revenue by Region (2016-2021e) & (USD Million)
Table 73. Asia-Pacific Biosimilar Insulin Glargine Revenue by Region (2021-2026) & (USD Million)
Table 74. Asia-Pacific Biosimilar Insulin Glargine Sales by Type (2016-2021e) & (K Units)
Table 75. Asia-Pacific Biosimilar Insulin Glargine Sales by Type (2021-2026) & (K Units)
Table 76. Asia-Pacific Biosimilar Insulin Glargine Sales by Application (2016-2021e) & (K Units)
Table 77. Asia-Pacific Biosimilar Insulin Glargine Sales by Application (2021-2026) & (K Units)
Table 78. South America Biosimilar Insulin Glargine Sales by Country (2016-2021e) & (K Units)
Table 79. South America Biosimilar Insulin Glargine Sales by Country (2021-2026) & (K Units)
Table 80. South America Biosimilar Insulin Glargine Revenue by Country (2016-2021e) & (USD Million)
Table 81. South America Biosimilar Insulin Glargine Revenue by Country (2021-2026) & (USD Million)
Table 82. South America Biosimilar Insulin Glargine Sales by Type (2016-2021e) & (K Units)
Table 83. South America Biosimilar Insulin Glargine Sales by Type (2021-2026) & (K Units)
Table 84. South America Biosimilar Insulin Glargine Sales by Application (2016-2021e) & (K Units)
Table 85. South America Biosimilar Insulin Glargine Sales by Application (2021-2026) & (K Units)
Table 86. Middle East & Africa Biosimilar Insulin Glargine Sales by Country (2016-2021e) & (K Units)
Table 87. Middle East & Africa Biosimilar Insulin Glargine Sales by Country (2021-2026) & (K Units)
Table 88. Middle East & Africa Biosimilar Insulin Glargine Revenue by Country (2016-2021e) & (USD Million)
Table 89. Middle East & Africa Biosimilar Insulin Glargine Revenue by Country (2021-2026) & (USD Million)
Table 90. Middle East & Africa Biosimilar Insulin Glargine Sales by Type (2016-2021e) & (K Units)
Table 91. Middle East & Africa Biosimilar Insulin Glargine Sales by Type (2021-2026) & (K Units)
Table 92. Middle East & Africa Biosimilar Insulin Glargine Sales by Application (2016-2021e) & (K Units)
Table 93. Middle East & Africa Biosimilar Insulin Glargine Sales by Application (2021-2026) & (K Units)
Table 94. Direct Channel Pros & Cons
Table 95. Indirect Channel Pros & Cons
Table 96. Biosimilar Insulin Glargine Typical Distributors
Table 97. Biosimilar Insulin Glargine Typical Customers
List of Figures
Figure 1. Biosimilar Insulin Glargine Picture
Figure 2. Global Biosimilar Insulin Glargine Sales Market Share by Type in 2020
Figure 3. Pre-filled
Figure 4. Cartridge
Figure 5. Global Biosimilar Insulin Glargine Sales Market Share by Application in 2020
Figure 6. Hospital
Figure 7. Retail Pharmacy
Figure 8. Others
Figure 9. Global Biosimilar Insulin Glargine Market Size, (USD Million) & (K Units): 2020 VS 2021 VS 2026
Figure 10. Global Biosimilar Insulin Glargine Market Size and Forecast (2016-2026) & (USD Million)
Figure 11. Global Biosimilar Insulin Glargine Sales (2016-2026) & (K Units)
Figure 12. Global Biosimilar Insulin Glargine Price by Type (2016-2026) & (US$/Unit)
Figure 13. Global Biosimilar Insulin Glargine Production Capacity (2016-2026) & (K Units)
Figure 14. Global Biosimilar Insulin Glargine Production Capacity by Geographic Region: 2020 VS 2021
Figure 15. Biosimilar Insulin Glargine Market Drivers
Figure 16. Biosimilar Insulin Glargine Market Restraints
Figure 17. Biosimilar Insulin Glargine Market Trends
Figure 18. Global Biosimilar Insulin Glargine Sales Market Share by Manufacturer in 2020
Figure 19. Global Biosimilar Insulin Glargine Revenue Market Share by Manufacturer in 2020
Figure 20. Biosimilar Insulin Glargine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 21. Top 3 Biosimilar Insulin Glargine Manufacturer (Revenue) Market Share in 2020
Figure 22. Top 6 Biosimilar Insulin Glargine Manufacturer (Revenue) Market Share in 2020
Figure 23. Global Biosimilar Insulin Glargine Sales Market Share by Region (2016-2026)
Figure 24. Global Biosimilar Insulin Glargine Revenue Market Share by Region (2016-2026)
Figure 25. North America Biosimilar Insulin Glargine Revenue (2016-2026) & (USD Million)
Figure 26. Europe Biosimilar Insulin Glargine Revenue (2016-2026) & (USD Million)
Figure 27. Asia-Pacific Biosimilar Insulin Glargine Revenue (2016-2026) & (USD Million)
Figure 28. South America Biosimilar Insulin Glargine Revenue (2016-2026) & (USD Million)
Figure 29. Middle East & Africa Biosimilar Insulin Glargine Revenue (2016-2026) & (USD Million)
Figure 30. Global Biosimilar Insulin Glargine Sales Market Share by Type (2016-2026)
Figure 31. Global Biosimilar Insulin Glargine Revenue Market Share by Type (2016-2026)
Figure 32. Global Biosimilar Insulin Glargine Price by Type (2016-2026) & (US$/Unit)
Figure 33. Global Biosimilar Insulin Glargine Sales Market Share by Application (2016-2026)
Figure 34. Global Biosimilar Insulin Glargine Revenue Market Share by Application (2016-2026)
Figure 35. Global Biosimilar Insulin Glargine Price by Application (2016-2026) & (US$/Unit)
Figure 36. North America Biosimilar Insulin Glargine Sales Market Share by Type (2016-2026)
Figure 37. North America Biosimilar Insulin Glargine Sales Market Share by Application (2016-2026)
Figure 38. North America Biosimilar Insulin Glargine Sales Market Share by Country (2016-2026)
Figure 39. North America Biosimilar Insulin Glargine Revenue Market Share by Country (2016-2026)
Figure 40. United States Biosimilar Insulin Glargine Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 41. Canada Biosimilar Insulin Glargine Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 42. Mexico Biosimilar Insulin Glargine Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 43. Europe Biosimilar Insulin Glargine Sales Market Share by Type (2016-2026)
Figure 44. Europe Biosimilar Insulin Glargine Sales Market Share by Application (2016-2026)
Figure 45. Europe Biosimilar Insulin Glargine Sales Market Share by Country (2016-2026)
Figure 46. Europe Biosimilar Insulin Glargine Revenue Market Share by Country (2016-2026)
Figure 47. Germany Biosimilar Insulin Glargine Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 48. France Biosimilar Insulin Glargine Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 49. United Kingdom Biosimilar Insulin Glargine Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 50. Russia Biosimilar Insulin Glargine Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 51. Italy Biosimilar Insulin Glargine Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 52. Asia-Pacific Biosimilar Insulin Glargine Sales Market Share by Region (2016-2026)
Figure 53. Asia-Pacific Biosimilar Insulin Glargine Sales Market Share by Application (2016-2026)
Figure 54. Asia-Pacific Biosimilar Insulin Glargine Sales Market Share by Region (2016-2026)
Figure 55. Asia-Pacific Biosimilar Insulin Glargine Revenue Market Share by Region (2016-2026)
Figure 56. China Biosimilar Insulin Glargine Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 57. Japan Biosimilar Insulin Glargine Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 58. Korea Biosimilar Insulin Glargine Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 59. India Biosimilar Insulin Glargine Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 60. Southeast Asia Biosimilar Insulin Glargine Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. Australia Biosimilar Insulin Glargine Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. South America Biosimilar Insulin Glargine Sales Market Share by Type (2016-2026)
Figure 63. South America Biosimilar Insulin Glargine Sales Market Share by Application (2016-2026)
Figure 64. South America Biosimilar Insulin Glargine Sales Market Share by Country (2016-2026)
Figure 65. South America Biosimilar Insulin Glargine Revenue Market Share by Country (2016-2026)
Figure 66. Brazil Biosimilar Insulin Glargine Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 67. Argentina Biosimilar Insulin Glargine Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 68. Middle East & Africa Biosimilar Insulin Glargine Sales Market Share by Type (2016-2026)
Figure 69. Middle East & Africa Biosimilar Insulin Glargine Sales Market Share by Application (2016-2026)
Figure 70. Middle East & Africa Biosimilar Insulin Glargine Sales Market Share by Country (2016-2026)
Figure 71. Middle East & Africa Biosimilar Insulin Glargine Revenue Market Share by Country (2016-2026)
Figure 72. Turkey Biosimilar Insulin Glargine Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 73. Egypt Biosimilar Insulin Glargine Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 74. Saudi Arabia Biosimilar Insulin Glargine Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 75. South Africa Biosimilar Insulin Glargine Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 76. Sales Channel: Direct Channel vs Indirect Channel
Figure 77. Methodology
Figure 78. Research Process and Data Source

---